SciBX
Science-Business eXchange

THE DISTILLERY

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Tissue factor	Mouse studies suggest inhibiting the tissue factor–activated coagulation cascade could help treat cancer. In a mouse model of breast cancer, two doxorubicin prodrugs that targeted coagulation-associated serum proteases accumulated in the tumor, which decreased tumor growth and lung metastases and prolonged mouse survival compared with doxorubicin control. Next steps include selecting a lead compound. Eisai Co. Ltd.'s MORAb-066, a humanized mAb against tissue factor, is in preclinical testing to treat pancreatic cancer. Genmab A/S's HuMax-TF tissue factor mAb is in preclinical testing to treat cancer. Affinity Pharmaceuticals Inc. did not disclose their next steps. *SciBX* 4(37); doi:10.1038/scibx.2011.1039 Published online Sept. 22, 2011	Patent application filed; licensed by Affinity Pharmaceuticals; available for licensing, collaboration and investment	Liu, Y. *et al. Cancer Res.*; published online Aug. 31, 2011; doi:10.1158/0008-5472.CAN-11-1145 **Contact:** Cheng Liu, The Scripps Research Institute, La Jolla, Calif. e-mail: chengliu@scripps.edu